计划状态
招聘阶段
第 1 阶段 第二阶段允许先接受免疫治疗
是CRC 指导的试验
是药物
BMS-936558-01, BMS-986340标签
MSI-H/ MMRd、MSS/ MMRp评论
BMS-986340 (anti-CCR8 monoclonal antibody) monotherapy and later in combination with nivolumab (anti PD-1, immunotherapy)
| 地点 | 位置状态 |
|---|---|
| 美国 | |
|
Community Cancer Institute Clovis, California 93611 |
招聘 |
|
USC/Norris Comprehensive Cancer Center 加利福尼亚州洛杉矶 90033 |
招聘 |
|
长老会胡格纪念医院 加利福尼亚州纽波特海滩 92663 |
招聘 |
|
爱荷华大学 爱荷华州爱荷华市 52242 |
招聘 |
|
John Theurer Cancer Center 新泽西州哈肯萨克 07601 |
招聘 |
|
Columbia University Irving Medical Center 纽约州纽约市 10032 |
招聘 |
|
地方机构 - 0002 纽约州纽约市 10065 |
已完成 |
|
Providence Cancer Center Oncology and Hematology Care- Eastside 俄勒冈州波特兰 97213 |
招聘 |
|
Local Institution - 0063 Nashville, Tennessee 37067 |
尚未招聘 |
|
Vanderbilt University Medical Center 田纳西州纳什维尔 37232 |
招聘 |
|
Houston Methodist Hospital 德克萨斯州休斯顿 77030 |
招聘 |
| 澳大利亚 | |
|
Blacktown Hospital Blacktown, New South Wales 2148 |
招聘 |
|
Liverpool Hospital Liverpool, New South Wales 2170 |
招聘 |
|
亚历山德拉公主医院 Brisbane, Queensland 4102 |
招聘 |
|
Cabrini Hospital - Malvern Malvern, Victoria 3144 |
招聘 |
|
St Vincent's Hospital Melbourne, Victoria 3065 |
招聘 |
|
One Clinical Research 西澳大利亚奈德兰兹 6009 |
招聘 |
| 加拿大 | |
|
Cross Cancer Institute Edmonton, Alberta T6X 1E8 |
招聘 |
|
BC Cancer Vancouver 不列颠哥伦比亚省温哥华 V5Z 4E6 |
招聘 |
|
Hamilton Health Sciences-Juravinski Cancer Centre Hamilton, Ontario L8V5C2 |
招聘 |
|
地方机构 - 0009 安大略省多伦多 M5G 2M9 |
已完成 |
|
Centre Hospitalier de luniversite de Montreal Montreal, Quebec H2X 0A9 |
招聘 |
|
The Ottawa Hospital Cancer Centre 渥太华 K1H 8L6 |
招聘 |
| 德国 | |
|
Universitaetsklinikum Ulm Ulm, Baden-Wurttemberg 89081 |
招聘 |
|
Universitaetsklinikum Carl Gustav Carus Dresden-University Cancer Center Early Clinical Trial Unit 德累斯顿 01307 |
招聘 |
|
Universitaetsklinikum Essen Essen 45147 |
招聘 |
|
Universitatsklinikum Frankfurt Frankfurt 60590 |
招聘 |
|
Universitaetsklinikum Wuerzburg Wuerzburg 97078 |
招聘 |
| 以色列 | |
|
拉宾医疗中心 Petah Tikva, HaMerkaz 4941492 |
招聘 |
|
地方机构 - 0035 Ramat Gan, HaMerkaz 5265601 |
撤回 |
|
示巴医疗中心 Ramat Gan, HaMerkaz 5265601 |
招聘 |
|
兰巴姆医疗保健园区 Haifa, HaTsafon 3109601 |
招聘 |
|
Sourasky Medical Center Tel Aviv, Tell Abīb 6423906 |
招聘 |
| 意大利 | |
|
Humanitas Rozzano, Milano 20089 |
招聘 |
|
Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia Candiolo, Torino 10060 |
招聘 |
|
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 Milan 20133 |
招聘 |
|
Istituto Nazionale Tumori IRCCS Fondazione Pascale 那不勒斯 80131 |
招聘 |
|
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Universita Cattolica del Sacro Cuore 罗马 00168 |
招聘 |
|
ospedale le scotte-U.O.C. Immunoterapia Oncologica Siena 53100 |
招聘 |
| 日本 | |
|
国家癌症中心东区医院 Kashiwa, Chiba 277-8577 |
招聘 |
| 西班牙 | |
|
Hospital Universitario Virgen de la Victoria Málaga, Andalucía 29010 |
招聘 |
|
Institut Catalan d Oncologia (ICO) - Badalona Badalona, Barcelona [Barcelona] 08916 |
招聘 |
|
瓦尔德希伯伦大学医院 巴塞罗那, 巴塞罗那 [Barcelona] 08035 |
招聘 |
|
十月十二日大学医院 Madrid, Madrid, Comunidad De 28041 |
招聘 |
|
Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD 马德里 28040 |
招聘 |
|
Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid-CIOCC 马德里 28050 |
招聘 |
|
Clinica Universidad de Navarra-oNCOLOGY 潘普洛纳 31008 |
招聘 |
联系方式
联系
纳入标准
纳入标准
* Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis
* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are not acceptable.
* 东部合作肿瘤学组表现状态为 0 或 1
* Radiographically documented progressive disease on or after the most recent therapy
* Received standard-of-care therapies, (except for Part 1C, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated
* Advanced or metastatic disease and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant
排除标准
排除标准：
* Women who are pregnant or breastfeeding
* Primary central nervous system (CNS) malignancy
* Untreated CNS metastases
* Leptomeningeal metastases
* Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment
* Active, known, or suspected autoimmune disease
* Condition requiring systemic treatment with either corticosteroids within 14 days or other immunosuppressive medications within 30 days of the first dose of study treatment
* Prior organ or tissue allograft
* Uncontrolled or significant cardiovascular disease
* Major surgery within 4 weeks of study drug administration
* History of or with active interstitial lung disease or pulmonary fibrosis
适用协议规定的其他纳入/排除标准
